董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jose R. Rodriguez | 男 | Director, Chairman of the Board | 63 | 19.84万美元 | 未持股 | 2022-10-03 |
| David J. Shulkin | 男 | Director | 62 | 18.29万美元 | 未持股 | 2022-10-03 |
| Carlos A. de Solo | 男 | Director, Chief Executive Officer | 43 | 154.16万美元 | 未持股 | 2022-10-03 |
| Beatriz Assapimonwait | 女 | Director | 60 | 16.42万美元 | 未持股 | 2022-10-03 |
| Jennifer Carter | 女 | Director | 58 | 18.29万美元 | 未持股 | 2022-10-03 |
| Bryan Cho | 男 | Director | 49 | 15.77万美元 | 未持股 | 2022-10-03 |
| Vincent Omachonu | 男 | Director | 68 | 14.82万美元 | 未持股 | 2022-10-03 |
| Randy Simpson | 男 | Director | 53 | 18.29万美元 | 未持股 | 2022-10-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carlos A. de Solo | 男 | Director, Chief Executive Officer | 43 | 154.16万美元 | 未持股 | 2022-10-03 |
| Kevin Wirges | 男 | Chief Financial Officer | 43 | 81.90万美元 | 未持股 | 2022-10-03 |
| Alberto de Solo | 男 | Chief Operating Officer | 45 | 99.81万美元 | 未持股 | 2022-10-03 |
董事简历
中英对照 | 中文 | 英文- Jose R. Rodriguez
-
Jose R.Rodriguez将于2021年3月31日从毕马威会计师事务所退休。Rodriguez先生是高级审计合伙人（1995年7月加入合伙企业）。在毕马威的职业生涯中，他担任过多个领导职位，包括在其董事会任职，并担任首席董事；毕马威国际公司（KPMG International）的全球审计实践首席运营官；办公室管理合伙人；其审计委员会研究所（ACI）的领导人；东部地区专业实践合伙人和最近的监察员。作为审计合伙人，Rodriguez先生在大型跨国公司和中型私营和上市公司拥有丰富经验，主要侧重于工业制造；消费者市场（零售、汽车和分销业务）；制药；农业综合企业；石油和天然气以及并购，罗德里格斯是NACD的研究员，并被列入NACD的D-100榜单，该榜单表彰了董事会中和董事会周围最有影响力的人。Rodriguez先生任职于Marymount University的董事会；拉丁美洲公司董事协会（财务主管）、SECU Family House（当选主席）、北卡罗来纳州注册会计师协会的董事会，迈阿密大学赫伯特商学院院长顾问委员会（主席）和维克森林大学商学院顾问委员会。他是一名注册会计师（在佛罗里达州、北卡罗来纳州和纽约州获得执照）。Rodriguez先生获得了迈阿密大学会计专业的学士学位。
Jose R. Rodriguez,has served as one of Directors since May 2021. He is a retired senior audit partner from KPMG, where he served for over 25 years. During his career at KPMG he held various leadership positions, which included serving on its Board of Directors and as lead Director; chief operating officer of KPMG International's global audit practice; office managing partner; leader of its Audit Committee Institute (ACI); east region professional practice partner and most recently ombudsman. As an audit partner, Mr. Rodriguez had extensive experience with large multinational companies and mid-size private and publicly held companies, with primary emphasis on industrial manufacturing; consumer markets (retail, automotive, and distribution concerns); pharmaceuticals; agribusiness; oil and gas and mergers and acquisitions. Additionally, Mr. Rodriguez is a NACD Fellow and has been included in NACD's D-100 list, which recognizes the most influential people in and around the Boardroom.Mr. Rodriguez currently serves on the Board of Popular, Inc (Nasdaq:BPOP) since June 2021, where he serves on the Audit Committee and Risk Committee. Mr. Rodriguez previously served on the Board of CareMax, Inc (Nasdaq:CMAX) from June 2021 to February 2025, where he was Chair of the Board, Chair of the Audit Committee and a member of the Compliance Committee.Mr. Rodriguez serves on the Board of trustees of Marymount University; Board of Directors of Latin Corporate Directors Association (first Vice Chair), SECU Family House (Chair), the North Carolina Association of CPAs (Chair-elect), the Dean's Advisory Council at the University of Miami Herbert School of Business (Chair) and the Business School Advisory Board at Wake Forest University. He is a certified public accountant (licensed in FL, NC and NY). Mr. Rodriguez received a B.B.A with a major in accounting from the University of Miami. - Jose R.Rodriguez将于2021年3月31日从毕马威会计师事务所退休。Rodriguez先生是高级审计合伙人（1995年7月加入合伙企业）。在毕马威的职业生涯中，他担任过多个领导职位，包括在其董事会任职，并担任首席董事；毕马威国际公司（KPMG International）的全球审计实践首席运营官；办公室管理合伙人；其审计委员会研究所（ACI）的领导人；东部地区专业实践合伙人和最近的监察员。作为审计合伙人，Rodriguez先生在大型跨国公司和中型私营和上市公司拥有丰富经验，主要侧重于工业制造；消费者市场（零售、汽车和分销业务）；制药；农业综合企业；石油和天然气以及并购，罗德里格斯是NACD的研究员，并被列入NACD的D-100榜单，该榜单表彰了董事会中和董事会周围最有影响力的人。Rodriguez先生任职于Marymount University的董事会；拉丁美洲公司董事协会（财务主管）、SECU Family House（当选主席）、北卡罗来纳州注册会计师协会的董事会，迈阿密大学赫伯特商学院院长顾问委员会（主席）和维克森林大学商学院顾问委员会。他是一名注册会计师（在佛罗里达州、北卡罗来纳州和纽约州获得执照）。Rodriguez先生获得了迈阿密大学会计专业的学士学位。
- Jose R. Rodriguez,has served as one of Directors since May 2021. He is a retired senior audit partner from KPMG, where he served for over 25 years. During his career at KPMG he held various leadership positions, which included serving on its Board of Directors and as lead Director; chief operating officer of KPMG International's global audit practice; office managing partner; leader of its Audit Committee Institute (ACI); east region professional practice partner and most recently ombudsman. As an audit partner, Mr. Rodriguez had extensive experience with large multinational companies and mid-size private and publicly held companies, with primary emphasis on industrial manufacturing; consumer markets (retail, automotive, and distribution concerns); pharmaceuticals; agribusiness; oil and gas and mergers and acquisitions. Additionally, Mr. Rodriguez is a NACD Fellow and has been included in NACD's D-100 list, which recognizes the most influential people in and around the Boardroom.Mr. Rodriguez currently serves on the Board of Popular, Inc (Nasdaq:BPOP) since June 2021, where he serves on the Audit Committee and Risk Committee. Mr. Rodriguez previously served on the Board of CareMax, Inc (Nasdaq:CMAX) from June 2021 to February 2025, where he was Chair of the Board, Chair of the Audit Committee and a member of the Compliance Committee.Mr. Rodriguez serves on the Board of trustees of Marymount University; Board of Directors of Latin Corporate Directors Association (first Vice Chair), SECU Family House (Chair), the North Carolina Association of CPAs (Chair-elect), the Dean's Advisory Council at the University of Miami Herbert School of Business (Chair) and the Business School Advisory Board at Wake Forest University. He is a certified public accountant (licensed in FL, NC and NY). Mr. Rodriguez received a B.B.A with a major in accounting from the University of Miami.
- David J. Shulkin
-
David J.Shulkin担任我们的董事会主席。Shamir先生担任路明克斯公司的董事长，总裁兼首席执行官，该公司开发，制造和销售各种专有的生物测试技术，他于2014年10月加入该公司。Shamir先生曾于2006年至2014年担任Given Imaging的总裁兼首席执行官，该公司是胃肠道疾病可视化和检测诊断产品的开发商，制造商和营销商。在加入Given Imaging之前，Shamir先生是Eastman Kodak Company的公司副总裁和Eastman Kodak´；s交易和工业解决方案集团的总裁。此外，他曾任职Scitex Corporation10年以上，担任越来越重要的职务，包括总裁兼首席执行官（从2003年到2004年）。在2003年之前，Shamir先生在多家国际公司担任高级管理职位，主要在亚太地区。Shamir先生拥有耶路撒冷希伯来大学的理学学士学位和哈佛大学的公共管理硕士学位。
David J. Shulkin,became a member of the Board in April 2020 and serves as a member of the Compensation Committee Since 2018, he has served as President and CEO of Shulkin Solutions, Inc., a company that promotes innovation in healthcare and advocates for veterans and underserved populations. From July 2015 through March 2018, Dr. Shulkin served in various capacities at the U.S. Department of Veterans Affairs (the "VA"), including as Secretary of the VA from February 2017 to March 2018 and as Under Secretary for Health from July 2015 to February 2017. Prior to his tenure at the VA, he served in executive leadership positions at Morristown Medical Center, Beth Israel Medical Center, Temple University Hospital, Drexel University School of Medicine, Doctor Quality, Inc. and the University of Pennsylvania Health System and Hospital of the University of Pennsylvania. Dr. Shulkin received a B.A. from Hampshire College and his M.D. from the Medical College of Pennsylvania (Drexel College of Medicine). He also completed residencies in Internal Medicine at Yale University School of Medicine and University of Pittsburgh School of Medicine, was a Fellow in General Medicine at the University of Pittsburgh School of Medicine and was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania School of Medicine. Dr. Shulkin is certified by the American Board of Internal Medicine. - David J.Shulkin担任我们的董事会主席。Shamir先生担任路明克斯公司的董事长，总裁兼首席执行官，该公司开发，制造和销售各种专有的生物测试技术，他于2014年10月加入该公司。Shamir先生曾于2006年至2014年担任Given Imaging的总裁兼首席执行官，该公司是胃肠道疾病可视化和检测诊断产品的开发商，制造商和营销商。在加入Given Imaging之前，Shamir先生是Eastman Kodak Company的公司副总裁和Eastman Kodak´；s交易和工业解决方案集团的总裁。此外，他曾任职Scitex Corporation10年以上，担任越来越重要的职务，包括总裁兼首席执行官（从2003年到2004年）。在2003年之前，Shamir先生在多家国际公司担任高级管理职位，主要在亚太地区。Shamir先生拥有耶路撒冷希伯来大学的理学学士学位和哈佛大学的公共管理硕士学位。
- David J. Shulkin,became a member of the Board in April 2020 and serves as a member of the Compensation Committee Since 2018, he has served as President and CEO of Shulkin Solutions, Inc., a company that promotes innovation in healthcare and advocates for veterans and underserved populations. From July 2015 through March 2018, Dr. Shulkin served in various capacities at the U.S. Department of Veterans Affairs (the "VA"), including as Secretary of the VA from February 2017 to March 2018 and as Under Secretary for Health from July 2015 to February 2017. Prior to his tenure at the VA, he served in executive leadership positions at Morristown Medical Center, Beth Israel Medical Center, Temple University Hospital, Drexel University School of Medicine, Doctor Quality, Inc. and the University of Pennsylvania Health System and Hospital of the University of Pennsylvania. Dr. Shulkin received a B.A. from Hampshire College and his M.D. from the Medical College of Pennsylvania (Drexel College of Medicine). He also completed residencies in Internal Medicine at Yale University School of Medicine and University of Pittsburgh School of Medicine, was a Fellow in General Medicine at the University of Pittsburgh School of Medicine and was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania School of Medicine. Dr. Shulkin is certified by the American Board of Internal Medicine.
- Carlos A. de Solo
-
Carlos A. de Solo自2021年6月8日起担任Caremax公司总裁兼首席执行官和董事。de Solo先生是CareMax医疗集团（“CareMax”）的联合创始人兼总裁兼首席执行官，并于2011年5月至2021年6月8日担任该职务。de Solo先生在医疗保健行业拥有10年以上的经验。在共同创立CareMax之前，德索罗先生曾担任Solera Health Systems，LLC的首席运营官和合伙人，Solera Health Systems，LLC是一家由医疗保健管理的初创公司。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
Carlos A. de Solo has served as Caremax, Inc. President and Chief Executive Officer, and as a director, since June 8, 2021. Mr. de Solo was a co-founder and the President and Chief Executive Officer of CareMax Medical Group, L.L.C. ("CMG"), and served in those capacities from May 2011 until June 8, 2021. Mr. de Solo has more than 10 years of experience in the healthcare industry. Prior to co-founding CareMax, Mr. de Solo served as Chief Operating Officer and partner of Solera Health Systems, LLC a startup managed healthcare company. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University. - Carlos A. de Solo自2021年6月8日起担任Caremax公司总裁兼首席执行官和董事。de Solo先生是CareMax医疗集团（“CareMax”）的联合创始人兼总裁兼首席执行官，并于2011年5月至2021年6月8日担任该职务。de Solo先生在医疗保健行业拥有10年以上的经验。在共同创立CareMax之前，德索罗先生曾担任Solera Health Systems，LLC的首席运营官和合伙人，Solera Health Systems，LLC是一家由医疗保健管理的初创公司。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
- Carlos A. de Solo has served as Caremax, Inc. President and Chief Executive Officer, and as a director, since June 8, 2021. Mr. de Solo was a co-founder and the President and Chief Executive Officer of CareMax Medical Group, L.L.C. ("CMG"), and served in those capacities from May 2011 until June 8, 2021. Mr. de Solo has more than 10 years of experience in the healthcare industry. Prior to co-founding CareMax, Mr. de Solo served as Chief Operating Officer and partner of Solera Health Systems, LLC a startup managed healthcare company. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University.
- Beatriz Assapimonwait
-
Beatriz Assapimonwait自2021年9月14日起担任董事会独立董事。她在管理式医疗行业拥有超过39年的经验。Assapimonwait女士在2021年8月之前一直担任Humana Inc.（纽约证券交易所代码：HUM）南佛罗里达地区的区域总裁，该公司是美国最大的私人保险健康保险公司之一，专注于管理Medicare Advantage计划。Assapimonwait女士在Humana公司任职期间，负责制定市场战略，领导所有医疗保险业务线的所有市场业务，包括南佛罗里达地区的HMO和PPO。在加入Humana之前，她曾担任Winter Park，Inc.的Family Physicians的首席执行官，直到该公司被Humana Inc.收购，2016年12月至2019年7月，她领导了一家在佛罗里达州中部地区拥有22家初级诊所的全球风险MSO的战略和运营工作。此外，她曾于2014年11月至2016年11月担任Aetna，Inc.医疗保险优势处方药计划副总裁；2014年1月至2014年10月担任Innovacare Health首席运营官；2013年7月至2013年12月担任Seven Stars Quality Healthcare Founder兼总裁；2009年1月至2013年6月担任Humana Inc.北佛罗里达地区总裁。Assapimonwait女士于1983年在佛罗里达国际大学获得文学学士学位，并获得医疗保健合规协会的医疗保健合规认证和肯尼索州立大学的HIPAA合规认证。她赢得了多个奖项和表彰，包括2004年美国商业奖最佳客户服务组织的史蒂夫奖决赛入围者，并于1997年被任命为休斯顿-克利尔湖大学医疗管理项目的导师和临床兼职教师。
Beatriz Assapimonwait,has over 40 years of experience in the managed health care industry. Ms. Assapimonwait was, up until August 2021, Regional President for the South Florida region at Humana Inc. (NYSE:HUM) ("Humana"), one of the largest private insurance health insurers in the U.S. with a focus on administering Medicare Advantage plans. In her role at Humana, Ms. Assapimonwait was responsible for developing market strategies and leading all market operations for all Medicare lines of business, including HMOs and PPOs for the South Florida region. Prior to her role at Humana, she served as CEO of Family Physicians of Winter Park, Inc., until its acquisition by Humana, where from December 2016 to July 2019, she led the strategic and operational efforts of a global risk management services organization with 22 primary clinics in the Central Florida Region. Additionally, she served as the Vice President of Medicare Advantage Prescription Drug Plans at Aetna, Inc. from November 2014 to November 2016; Chief Operations Officer at Innovacare Health, from January 2014 to October 2014; Founder and President of Seven Stars Quality Healthcare, from July 2013 to December 2013; and Regional President for the North Florida region at Humana, from January 2009 to June 2013. Ms. Assapimonwait served on the board of directors and was Chair of the Strategy and Operations Committee of CareMax Inc. (Nasdaq:CMAX) from September 2021 to October 2023. She earned her Bachelor of Arts degree from Florida International University in 1983, and is certified in Healthcare Compliance by the Health Care Compliance Association and in HIPAA Compliance from Kennesaw State University. She has won several awards and commendations, including being a Stevie Award Finalist of the American Business Awards for Best Customer Service Organization in 2004 and appointed Preceptor and Clinical Adjunct Faculty for the Healthcare Administration Program in 1997 at the University of Houston-Clear Lake. - Beatriz Assapimonwait自2021年9月14日起担任董事会独立董事。她在管理式医疗行业拥有超过39年的经验。Assapimonwait女士在2021年8月之前一直担任Humana Inc.（纽约证券交易所代码：HUM）南佛罗里达地区的区域总裁，该公司是美国最大的私人保险健康保险公司之一，专注于管理Medicare Advantage计划。Assapimonwait女士在Humana公司任职期间，负责制定市场战略，领导所有医疗保险业务线的所有市场业务，包括南佛罗里达地区的HMO和PPO。在加入Humana之前，她曾担任Winter Park，Inc.的Family Physicians的首席执行官，直到该公司被Humana Inc.收购，2016年12月至2019年7月，她领导了一家在佛罗里达州中部地区拥有22家初级诊所的全球风险MSO的战略和运营工作。此外，她曾于2014年11月至2016年11月担任Aetna，Inc.医疗保险优势处方药计划副总裁；2014年1月至2014年10月担任Innovacare Health首席运营官；2013年7月至2013年12月担任Seven Stars Quality Healthcare Founder兼总裁；2009年1月至2013年6月担任Humana Inc.北佛罗里达地区总裁。Assapimonwait女士于1983年在佛罗里达国际大学获得文学学士学位，并获得医疗保健合规协会的医疗保健合规认证和肯尼索州立大学的HIPAA合规认证。她赢得了多个奖项和表彰，包括2004年美国商业奖最佳客户服务组织的史蒂夫奖决赛入围者，并于1997年被任命为休斯顿-克利尔湖大学医疗管理项目的导师和临床兼职教师。
- Beatriz Assapimonwait,has over 40 years of experience in the managed health care industry. Ms. Assapimonwait was, up until August 2021, Regional President for the South Florida region at Humana Inc. (NYSE:HUM) ("Humana"), one of the largest private insurance health insurers in the U.S. with a focus on administering Medicare Advantage plans. In her role at Humana, Ms. Assapimonwait was responsible for developing market strategies and leading all market operations for all Medicare lines of business, including HMOs and PPOs for the South Florida region. Prior to her role at Humana, she served as CEO of Family Physicians of Winter Park, Inc., until its acquisition by Humana, where from December 2016 to July 2019, she led the strategic and operational efforts of a global risk management services organization with 22 primary clinics in the Central Florida Region. Additionally, she served as the Vice President of Medicare Advantage Prescription Drug Plans at Aetna, Inc. from November 2014 to November 2016; Chief Operations Officer at Innovacare Health, from January 2014 to October 2014; Founder and President of Seven Stars Quality Healthcare, from July 2013 to December 2013; and Regional President for the North Florida region at Humana, from January 2009 to June 2013. Ms. Assapimonwait served on the board of directors and was Chair of the Strategy and Operations Committee of CareMax Inc. (Nasdaq:CMAX) from September 2021 to October 2023. She earned her Bachelor of Arts degree from Florida International University in 1983, and is certified in Healthcare Compliance by the Health Care Compliance Association and in HIPAA Compliance from Kennesaw State University. She has won several awards and commendations, including being a Stevie Award Finalist of the American Business Awards for Best Customer Service Organization in 2004 and appointed Preceptor and Clinical Adjunct Faculty for the Healthcare Administration Program in 1997 at the University of Houston-Clear Lake.
- Jennifer Carter
-
Jennifer Carter自2021年6月8日起担任董事会独立董事。Carter博士是医疗保健的一名高管、投资者、董事会成员和企业家，在医疗保健 IT与服务、数字健康和机器学习、精准医疗以及基因组学等细分领域的创新战略和解决方案的制定和投资方面拥有丰富的经验。自2021年3月以来，卡特博士一直担任Sandbox Industries和Blue Venture Fund的董事总经理。Sandbox Industries专门为Blue Venture Fund提供与医疗保健相关的投资管理。此前，Carter博士于2020年7月至2021年4月担任JLC Precision Health Strategies董事总经理，并于2019年3月至2020年8月担任旗舰公司Integral Health（现为Valo Health）的副总裁兼Precision Health负责人。2018年，Carter博士创立了TrialzOWN，Inc.，这是一家医疗保健公司，于2019年3月被Integral Health收购，该公司处于发展阶段。在担任TrialzOWN公司首席执行官之前，卡特博士创立了N-of-One公司，2008年至2012年担任首席执行官，2012年担任首席医疗官，直至2019年被Qiagen公司收购。在N-of-One，Inc.，Carter博士领导了该平台的开发，为癌症患者创建了屡获殊荣的新型治疗策略。在创立N-of-One之前，Carter博士曾在Levin Capital Strategies和其他专门从事生物技术和生命科学投资的集团担任投资顾问九年，评估现有和新兴市场、新医疗技术和早期公司。获得医学学位后，卡特博士在马萨诸塞州剑桥市的奥本山医院从事内科工作。自2020年起，卡特博士一直在Oncocyte（纳斯达克股票代码：OCX）和多家私营公司的董事会任职。Carter博士拥有耶鲁大学学士学位、哈佛医学院医学博士学位、哈佛大学公共卫生学院公共卫生硕士学位和MIT工商管理硕士学位。
Jennifer Carter has served as an independent director on the Board since June 8, 2021. Dr. Carter is a healthcare executive, investor, board member and entrepreneur with a track record of developing and investing in innovative strategies and solutions at the intersection of healthcare IT and services, digital health and machine learning, precision medicine, and genomics. Dr. Carter has been a Managing Director at Sandbox Industries and Blue Venture Fund since March 2021. Sandbox Industries provides healthcare-related investment management exclusively for the Blue Venture Fund. Previously, Dr. Carter served as Managing Director of JLC Precision Health Strategies from July 2020 to April 2021 and VP and Head of Precision Health at Integral Health (now Valo Health), a Flagship Pioneering company, from March 2019 to August 2020. In 2018, Dr. Carter founded TrialzOWN, Inc., a healthcare company that was acquired in the development stage by Integral Health in March 2019. Prior to serving as CEO of TrialzOWN, Inc. Dr. Carter founded N-of-One, Inc. and served as its Chief Executive Officer from 2008 to 2012, and as its Chief Medical Officer from 2012 until its acquisition by Qiagen in 2019. At N-of-One, Inc., Dr. Carter led the development of the platform to create of award-winning novel treatment strategies for cancer patients. Prior to founding N-of-One, Dr. Carter spent nine years working as an Investment Consultant with Levin Capital Strategies and with other groups specializing in biotechnology and life sciences investments evaluating existing and emerging markets, new medical technologies, and early-stage companies. After obtaining her medical degree, Dr. Carter practiced internal medicine at Mount Auburn Hospital in Cambridge, MA. Dr. Carter has served on the board of directors of Oncocyte (NASDAQ: OCX) since 2020 and multiple private companies. Dr. Carter received a BS degree from Yale University, an MD from Harvard Medical School, an MPH from the Harvard School of Public Health, and an MBA from MIT. - Jennifer Carter自2021年6月8日起担任董事会独立董事。Carter博士是医疗保健的一名高管、投资者、董事会成员和企业家，在医疗保健 IT与服务、数字健康和机器学习、精准医疗以及基因组学等细分领域的创新战略和解决方案的制定和投资方面拥有丰富的经验。自2021年3月以来，卡特博士一直担任Sandbox Industries和Blue Venture Fund的董事总经理。Sandbox Industries专门为Blue Venture Fund提供与医疗保健相关的投资管理。此前，Carter博士于2020年7月至2021年4月担任JLC Precision Health Strategies董事总经理，并于2019年3月至2020年8月担任旗舰公司Integral Health（现为Valo Health）的副总裁兼Precision Health负责人。2018年，Carter博士创立了TrialzOWN，Inc.，这是一家医疗保健公司，于2019年3月被Integral Health收购，该公司处于发展阶段。在担任TrialzOWN公司首席执行官之前，卡特博士创立了N-of-One公司，2008年至2012年担任首席执行官，2012年担任首席医疗官，直至2019年被Qiagen公司收购。在N-of-One，Inc.，Carter博士领导了该平台的开发，为癌症患者创建了屡获殊荣的新型治疗策略。在创立N-of-One之前，Carter博士曾在Levin Capital Strategies和其他专门从事生物技术和生命科学投资的集团担任投资顾问九年，评估现有和新兴市场、新医疗技术和早期公司。获得医学学位后，卡特博士在马萨诸塞州剑桥市的奥本山医院从事内科工作。自2020年起，卡特博士一直在Oncocyte（纳斯达克股票代码：OCX）和多家私营公司的董事会任职。Carter博士拥有耶鲁大学学士学位、哈佛医学院医学博士学位、哈佛大学公共卫生学院公共卫生硕士学位和MIT工商管理硕士学位。
- Jennifer Carter has served as an independent director on the Board since June 8, 2021. Dr. Carter is a healthcare executive, investor, board member and entrepreneur with a track record of developing and investing in innovative strategies and solutions at the intersection of healthcare IT and services, digital health and machine learning, precision medicine, and genomics. Dr. Carter has been a Managing Director at Sandbox Industries and Blue Venture Fund since March 2021. Sandbox Industries provides healthcare-related investment management exclusively for the Blue Venture Fund. Previously, Dr. Carter served as Managing Director of JLC Precision Health Strategies from July 2020 to April 2021 and VP and Head of Precision Health at Integral Health (now Valo Health), a Flagship Pioneering company, from March 2019 to August 2020. In 2018, Dr. Carter founded TrialzOWN, Inc., a healthcare company that was acquired in the development stage by Integral Health in March 2019. Prior to serving as CEO of TrialzOWN, Inc. Dr. Carter founded N-of-One, Inc. and served as its Chief Executive Officer from 2008 to 2012, and as its Chief Medical Officer from 2012 until its acquisition by Qiagen in 2019. At N-of-One, Inc., Dr. Carter led the development of the platform to create of award-winning novel treatment strategies for cancer patients. Prior to founding N-of-One, Dr. Carter spent nine years working as an Investment Consultant with Levin Capital Strategies and with other groups specializing in biotechnology and life sciences investments evaluating existing and emerging markets, new medical technologies, and early-stage companies. After obtaining her medical degree, Dr. Carter practiced internal medicine at Mount Auburn Hospital in Cambridge, MA. Dr. Carter has served on the board of directors of Oncocyte (NASDAQ: OCX) since 2020 and multiple private companies. Dr. Carter received a BS degree from Yale University, an MD from Harvard Medical School, an MPH from the Harvard School of Public Health, and an MBA from MIT.
- Bryan Cho
-
Bryan Cho自2021年7月13日起担任董事会独立董事。他是The Related Companies，L.P.（相关公司）的执行副总裁，也是该公司纽约和加利福尼亚开发部门的高级合伙人，还担任Related Senior Living业务的总裁，该业务目前有近25亿美元的在建物业。自2000年加入Related以来，Bryan领导了超过100亿美元的开发项目，在纽约市、洛杉矶和旧金山大都市区建造了近6000套新的多户住宅（包括1000多套新建的经济适用房）和超过600万平方英尺的商业和机构非营利空间。他是纽约市巴克利学校、纽约石溪石溪学校的董事会成员，也是纽约市无家可归者服务非营利组织鲍里教会的董事会成员，并担任教会房地产委员会主席。
Bryan Cho has served as an independent director of the Board since July 13, 2021. He is Executive Vice President of The Related Companies, L.P. ("Related") and a senior partner of the firm's New York and California development divisions, as well as president of Related's Senior Living business which currently has close to $2.5 billion in properties under development. Since joining Related in 2000, Bryan has led over $10.0 billion of development ventures creating close to 6,000 new multi-family residences (including over 1,000 units of new construction affordable housing) and over 6.0 million square feet of commercial and institutional non-profit space across the New York City, Los Angeles, and San Francisco metropolitan areas. He is a member of the board of trustees of The Buckley School in New York City, The Stony Brook School, in Stony Brook, New York, as well as a member of the board of directors of homeless services non-profit The Bowery Mission in New York City where he serves as Chair of the Mission's Real Estate Committee. - Bryan Cho自2021年7月13日起担任董事会独立董事。他是The Related Companies，L.P.（相关公司）的执行副总裁，也是该公司纽约和加利福尼亚开发部门的高级合伙人，还担任Related Senior Living业务的总裁，该业务目前有近25亿美元的在建物业。自2000年加入Related以来，Bryan领导了超过100亿美元的开发项目，在纽约市、洛杉矶和旧金山大都市区建造了近6000套新的多户住宅（包括1000多套新建的经济适用房）和超过600万平方英尺的商业和机构非营利空间。他是纽约市巴克利学校、纽约石溪石溪学校的董事会成员，也是纽约市无家可归者服务非营利组织鲍里教会的董事会成员，并担任教会房地产委员会主席。
- Bryan Cho has served as an independent director of the Board since July 13, 2021. He is Executive Vice President of The Related Companies, L.P. ("Related") and a senior partner of the firm's New York and California development divisions, as well as president of Related's Senior Living business which currently has close to $2.5 billion in properties under development. Since joining Related in 2000, Bryan has led over $10.0 billion of development ventures creating close to 6,000 new multi-family residences (including over 1,000 units of new construction affordable housing) and over 6.0 million square feet of commercial and institutional non-profit space across the New York City, Los Angeles, and San Francisco metropolitan areas. He is a member of the board of trustees of The Buckley School in New York City, The Stony Brook School, in Stony Brook, New York, as well as a member of the board of directors of homeless services non-profit The Bowery Mission in New York City where he serves as Chair of the Mission's Real Estate Committee.
- Vincent Omachonu
-
Vincent Omachonu自2021年6月8日起担任董事会独立董事。Omachonu博士是迈阿密大学工程学院工业和系统工程系的系主任。Omachonu博士是医疗保健质量管理和患者体验领域的一位屡获殊荣的专家和作家。他最近出版的一本书名为《医疗保健价值主张》。他在技术和专业期刊上发表了多篇经过同行评审的论文，包括Health Services Research、Journal of Population Health和European Journal of Operational Research。Omachonu博士撰写了大量有关服务业技术和创新的文章。他是精益六西格玛质量方法的黑带大师。他在迈阿密大学获得工业工程学士和硕士学位，在哥伦比亚大学获得运筹学硕士学位，在纽约大学坦顿工程学院获得工业工程博士学位。
Vincent Omachonu has served as an independent director on the Board since June 8, 2021. Dr. Omachonu is the Chair of the Department of Industrial and Systems Engineering at the University of Miami College of Engineering. Dr. Omachonu is an award-winning expert and author in the field of healthcare quality management and patient experience. His most recent book is titled, Healthcare Value Proposition. He has published several peer-reviewed papers in Technical and professional journals, including Health Services Research, Journal of Population Health, and European Journal of Operational Research. Dr. Omachonu has written extensively about technology and innovation in the services sector. He is a Master Black Belt in Lean Six Sigma Quality Methodology. He earned his bachelor's and master's degrees in industrial engineering from the University of Miami, a master's degree in operations research from Columbia University, and his PhD in industrial engineering from New York University Tandon School of Engineering. - Vincent Omachonu自2021年6月8日起担任董事会独立董事。Omachonu博士是迈阿密大学工程学院工业和系统工程系的系主任。Omachonu博士是医疗保健质量管理和患者体验领域的一位屡获殊荣的专家和作家。他最近出版的一本书名为《医疗保健价值主张》。他在技术和专业期刊上发表了多篇经过同行评审的论文，包括Health Services Research、Journal of Population Health和European Journal of Operational Research。Omachonu博士撰写了大量有关服务业技术和创新的文章。他是精益六西格玛质量方法的黑带大师。他在迈阿密大学获得工业工程学士和硕士学位，在哥伦比亚大学获得运筹学硕士学位，在纽约大学坦顿工程学院获得工业工程博士学位。
- Vincent Omachonu has served as an independent director on the Board since June 8, 2021. Dr. Omachonu is the Chair of the Department of Industrial and Systems Engineering at the University of Miami College of Engineering. Dr. Omachonu is an award-winning expert and author in the field of healthcare quality management and patient experience. His most recent book is titled, Healthcare Value Proposition. He has published several peer-reviewed papers in Technical and professional journals, including Health Services Research, Journal of Population Health, and European Journal of Operational Research. Dr. Omachonu has written extensively about technology and innovation in the services sector. He is a Master Black Belt in Lean Six Sigma Quality Methodology. He earned his bachelor's and master's degrees in industrial engineering from the University of Miami, a master's degree in operations research from Columbia University, and his PhD in industrial engineering from New York University Tandon School of Engineering.
- Randy Simpson
-
Randy Simpson自2021年6月8日起担任董事会独立董事。Simpson先生是Orion Acquisition Corp.（纳斯达克股票代码：OHPA）的联合创始人兼董事。最近，Simpson先生担任Glenview资本管理公司的合伙人兼医疗保健部门主管，该公司是一家投资基金，截至2019年管理着超过70亿美元的资本，他是Glenview投资团队的成员，并在2019年12月之前管理其医疗保健投资团队。Simpson先生于2005年9月加入Glenview资本管理公司，并于2011年4月被任命为合伙人。Simpson先生是Glenview资本管理公司投资团队的高级成员，在2019年之前一直管理Glenview资本管理公司的医疗保健投资。在加入Glenview资本管理公司之前，辛普森从2003年到2005年在高盛担任股票研究分析师，在此之前，他在瑞士信贷第一波士顿的并购集团担任了三年的通才。Simpson先生于2016年1月至2017年8月担任Tenet Healthcare公司（纽约证券交易所代码：THC）的董事会成员，并于2020年5月至2021年2月担任Butterfly Network, Inc.（纽约证券交易所代码：BFLY）的董事会成员。他在芝加哥大学获得了金融和会计硕士学位。Simpson先生还获得了乔治城大学法律中心的法学博士学位和加州大学圣地亚哥分校的数量经济学和决策科学文学士学位。辛普森先生不再竞选连任，他在董事会和各委员会的任期将在年会上结束。
Randy Simpson has served as an independent director on the Board since June 8, 2021. Mr. Simpson is the co-founder and a director of Orion Acquisition Corp. (NASDAQ: OHPA). Recently, Mr. Simpson served as a Partner and Head of the Healthcare Group at Glenview Capital Management, an investment fund with over $7 billion of capital under management as of 2019, where he was a member of Glenview's investment team and managed its healthcare investment team through December 2019. Mr. Simpson joined Glenview Capital Management in September 2005 and was named Partner in April 2011. Mr. Simpson was a senior member of Glenview Capital Management's investment team and managed Glenview Capital Management's healthcare investments through 2019. Prior to joining Glenview Capital Management, Mr. Simpson was an equity research analyst at Goldman Sachs from 2003 until 2005, and before that, he spent three years as a generalist in the M&A group at Credit Suisse First Boston. Mr. Simpson served on the Board of Directors of Tenet Healthcare Corporation (NYSE: THC) from January 2016 through August 2017 and Butterfly Network, Inc. (NYSE: BFLY) from May 2020 through February 2021. He received his M.B.A. in Finance and Accounting from the University of Chicago. Mr. Simpson also earned a J.D. from Georgetown University Law Center and a Bachelor of Arts in Quantitative Economics and Decision Sciences from the University of California, San Diego. Mr. Simpson is not standing for re-election and his service on the Board and committees will conclude at the Annual Meeting. - Randy Simpson自2021年6月8日起担任董事会独立董事。Simpson先生是Orion Acquisition Corp.（纳斯达克股票代码：OHPA）的联合创始人兼董事。最近，Simpson先生担任Glenview资本管理公司的合伙人兼医疗保健部门主管，该公司是一家投资基金，截至2019年管理着超过70亿美元的资本，他是Glenview投资团队的成员，并在2019年12月之前管理其医疗保健投资团队。Simpson先生于2005年9月加入Glenview资本管理公司，并于2011年4月被任命为合伙人。Simpson先生是Glenview资本管理公司投资团队的高级成员，在2019年之前一直管理Glenview资本管理公司的医疗保健投资。在加入Glenview资本管理公司之前，辛普森从2003年到2005年在高盛担任股票研究分析师，在此之前，他在瑞士信贷第一波士顿的并购集团担任了三年的通才。Simpson先生于2016年1月至2017年8月担任Tenet Healthcare公司（纽约证券交易所代码：THC）的董事会成员，并于2020年5月至2021年2月担任Butterfly Network, Inc.（纽约证券交易所代码：BFLY）的董事会成员。他在芝加哥大学获得了金融和会计硕士学位。Simpson先生还获得了乔治城大学法律中心的法学博士学位和加州大学圣地亚哥分校的数量经济学和决策科学文学士学位。辛普森先生不再竞选连任，他在董事会和各委员会的任期将在年会上结束。
- Randy Simpson has served as an independent director on the Board since June 8, 2021. Mr. Simpson is the co-founder and a director of Orion Acquisition Corp. (NASDAQ: OHPA). Recently, Mr. Simpson served as a Partner and Head of the Healthcare Group at Glenview Capital Management, an investment fund with over $7 billion of capital under management as of 2019, where he was a member of Glenview's investment team and managed its healthcare investment team through December 2019. Mr. Simpson joined Glenview Capital Management in September 2005 and was named Partner in April 2011. Mr. Simpson was a senior member of Glenview Capital Management's investment team and managed Glenview Capital Management's healthcare investments through 2019. Prior to joining Glenview Capital Management, Mr. Simpson was an equity research analyst at Goldman Sachs from 2003 until 2005, and before that, he spent three years as a generalist in the M&A group at Credit Suisse First Boston. Mr. Simpson served on the Board of Directors of Tenet Healthcare Corporation (NYSE: THC) from January 2016 through August 2017 and Butterfly Network, Inc. (NYSE: BFLY) from May 2020 through February 2021. He received his M.B.A. in Finance and Accounting from the University of Chicago. Mr. Simpson also earned a J.D. from Georgetown University Law Center and a Bachelor of Arts in Quantitative Economics and Decision Sciences from the University of California, San Diego. Mr. Simpson is not standing for re-election and his service on the Board and committees will conclude at the Annual Meeting.
高管简历
中英对照 | 中文 | 英文- Carlos A. de Solo
Carlos A. de Solo自2021年6月8日起担任Caremax公司总裁兼首席执行官和董事。de Solo先生是CareMax医疗集团（“CareMax”）的联合创始人兼总裁兼首席执行官，并于2011年5月至2021年6月8日担任该职务。de Solo先生在医疗保健行业拥有10年以上的经验。在共同创立CareMax之前，德索罗先生曾担任Solera Health Systems，LLC的首席运营官和合伙人，Solera Health Systems，LLC是一家由医疗保健管理的初创公司。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
Carlos A. de Solo has served as Caremax, Inc. President and Chief Executive Officer, and as a director, since June 8, 2021. Mr. de Solo was a co-founder and the President and Chief Executive Officer of CareMax Medical Group, L.L.C. ("CMG"), and served in those capacities from May 2011 until June 8, 2021. Mr. de Solo has more than 10 years of experience in the healthcare industry. Prior to co-founding CareMax, Mr. de Solo served as Chief Operating Officer and partner of Solera Health Systems, LLC a startup managed healthcare company. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University.- Carlos A. de Solo自2021年6月8日起担任Caremax公司总裁兼首席执行官和董事。de Solo先生是CareMax医疗集团（“CareMax”）的联合创始人兼总裁兼首席执行官，并于2011年5月至2021年6月8日担任该职务。de Solo先生在医疗保健行业拥有10年以上的经验。在共同创立CareMax之前，德索罗先生曾担任Solera Health Systems，LLC的首席运营官和合伙人，Solera Health Systems，LLC是一家由医疗保健管理的初创公司。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
- Carlos A. de Solo has served as Caremax, Inc. President and Chief Executive Officer, and as a director, since June 8, 2021. Mr. de Solo was a co-founder and the President and Chief Executive Officer of CareMax Medical Group, L.L.C. ("CMG"), and served in those capacities from May 2011 until June 8, 2021. Mr. de Solo has more than 10 years of experience in the healthcare industry. Prior to co-founding CareMax, Mr. de Solo served as Chief Operating Officer and partner of Solera Health Systems, LLC a startup managed healthcare company. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University.
- Kevin Wirges
Kevin Wirges自2021年6月8日起担任Caremax，Inc.执行副总裁、财务主管兼首席财务官。在2021年6月8日之前，Wirges先生曾担任IMC医疗集团控股有限公司的首席财务官，并于2017年9月起担任该职务。2015年10月至2017年9月，Wirges先生在美国最大的健康福利公司之一Anthem担任医疗保险东部地区财务副总裁。在Anthem于2015年收购Simply Healthcare Plans之前，Wirges先生曾在Simply Healthcare Plans担任多个行政职务，后者是最大的私营健康维护组织之一，包括首席财务官、财务副总裁和财务总监。Wirges先生获得了中阿肯色大学会计学学士学位。
Kevin Wirges has served as Caremax, Inc. Executive Vice President, Treasurer and Chief Financial Officer since June 8, 2021. Prior to June 8, 2021, Mr. Wirges was the Chief Financial Officer of IMC Medical Group Holdings, LLC and served in that capacity since September 2017. Between October 2015 and September 2017, Mr. Wirges was Regional Vice President, Finance, Medicare East Region at Anthem, one of the largest health benefits companies in the United States. Prior to Anthem's acquisition of Simply Healthcare Plans in 2015, Mr. Wirges held several executive positions at Simply Healthcare Plans, which was one of the largest privately owned Health Maintenance Organizations, including Chief Financial Officer, Vice President of Finance and Controller. Mr. Wirges received a B.B.A. in Accounting from the University of Central Arkansas.- Kevin Wirges自2021年6月8日起担任Caremax，Inc.执行副总裁、财务主管兼首席财务官。在2021年6月8日之前，Wirges先生曾担任IMC医疗集团控股有限公司的首席财务官，并于2017年9月起担任该职务。2015年10月至2017年9月，Wirges先生在美国最大的健康福利公司之一Anthem担任医疗保险东部地区财务副总裁。在Anthem于2015年收购Simply Healthcare Plans之前，Wirges先生曾在Simply Healthcare Plans担任多个行政职务，后者是最大的私营健康维护组织之一，包括首席财务官、财务副总裁和财务总监。Wirges先生获得了中阿肯色大学会计学学士学位。
- Kevin Wirges has served as Caremax, Inc. Executive Vice President, Treasurer and Chief Financial Officer since June 8, 2021. Prior to June 8, 2021, Mr. Wirges was the Chief Financial Officer of IMC Medical Group Holdings, LLC and served in that capacity since September 2017. Between October 2015 and September 2017, Mr. Wirges was Regional Vice President, Finance, Medicare East Region at Anthem, one of the largest health benefits companies in the United States. Prior to Anthem's acquisition of Simply Healthcare Plans in 2015, Mr. Wirges held several executive positions at Simply Healthcare Plans, which was one of the largest privately owned Health Maintenance Organizations, including Chief Financial Officer, Vice President of Finance and Controller. Mr. Wirges received a B.B.A. in Accounting from the University of Central Arkansas.
- Alberto de Solo
Alberto de Solo自2021年6月8日起担任Caremax，Inc.执行副总裁兼首席运营官。在2021年6月8日之前，德索罗先生是CMG的首席财务官，自2011年5月起担任该职务。2005年7月至2011年5月期间，德索罗先生在美林证券担任过多个行政职务。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
Alberto de Solo has served as Caremax, Inc. Executive Vice President and Chief Operating Officer since June 8, 2021. Prior to June 8, 2021, Mr. de Solo was the Chief Financial Officer of CMG and served in that capacity since May 2011. Between July 2005 and May 2011, Mr. de Solo held several executive positions at Merrill Lynch. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University.- Alberto de Solo自2021年6月8日起担任Caremax，Inc.执行副总裁兼首席运营官。在2021年6月8日之前，德索罗先生是CMG的首席财务官，自2011年5月起担任该职务。2005年7月至2011年5月期间，德索罗先生在美林证券担任过多个行政职务。de Solo先生在佛罗里达国际大学获得会计和金融学士学位。
- Alberto de Solo has served as Caremax, Inc. Executive Vice President and Chief Operating Officer since June 8, 2021. Prior to June 8, 2021, Mr. de Solo was the Chief Financial Officer of CMG and served in that capacity since May 2011. Between July 2005 and May 2011, Mr. de Solo held several executive positions at Merrill Lynch. Mr. de Solo received a B.B.A. in Accounting and Finance from Florida International University.